Aerosol Biology Small Animal Models

气溶胶生物学小动物模型

基本信息

批准号：
8446491
负责人：
Robert MARK Buller
金额：
$ 38.96万
依托单位：
WASHINGTON UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-03-01 至 2015-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8446491
关键词：
A Mouse A/J Mouse Aerosols Alanine Transaminase Animal Model Animals Antigens Antiviral Agents Award Bacillus anthracis Basic Science Biological Assay Biology Biotechnology Blood CD8B1 gene Categories Cells Clinical Country Development Disease Disease Progression Early Intervention Ectromelia Emerging Communicable Diseases Genome Hamsters Health Histology IACUC Immune response Infection Infectious Agent Intervention Laboratories Learning Licensure Modeling Modified Vaccinia Virus Ankara Monkeypox Monkeypox virus Mouse Pox Virus Mus Myoxidae Natural Killer Cells Orthopoxvirus Phase I Clinical Trials Preclinical Testing Protocols documentation Public Health Qualifying Reporting Research Research Personnel Respiratory System Respiratory tract structure Route SARS coronavirus Sampling Services Smallpox Specimen T-Lymphocyte Telemetry Temperature Testing Therapeutic Tissues Treatment Efficacy Vaccinia virus Viral Virus Work Writing aerosolized biodefense cytokine efficacy testing granulocyte immunosuppressed in vivo influenzavirus institutional biosafety committee monocyte pathogen prophylactic protocol development respiratory sample collection surgical service weapons

项目摘要

During the first award period the MRCE Aerosol Biology/Small Animal Models Core D (Core D) supported smallpox disease research (using ectromelia, monkeypox, and vaccinia viruses) as this disease was one of the most intensely modeled in Region 7. With licensure of Modified Vaccinia Ankara (MVA) and the availability of ACAM 2000¿ (derived from Dryvax¿), and phase I clinical trials of orthopoxvirus antivirals, ST-246 and CMX001, there is a diminishing need for in vivo testing of additional orthopoxvirus therapeutics and prophylactics. There is, however, still much to learn concerning the innate immune response to orthopxviruses and other infectious agents. The capacity of Core D to create additional models for use in basic research and prophylactic and therapeutic efficacy testing was under-scored by the development of the following five lethal challenge models: influenza virus A in C57BL/6-sfaH

在第一个奖励期内，MRCE 气溶胶生物学/小动物模型核心 D (Core D) 支持天花疾病研究（使用天花病毒、猴痘病毒和牛痘病毒），因为这种疾病是其中之一 7 区建模最密集。拥有 Modified Vaccinia Ankara (MVA) 和 ACAM 2000 的可用性¿ （源自 Dryvax¿），以及正痘病毒抗病毒药物的 I 期临床试验， ST-246 和 CMX001，对其他正痘病毒疗法的体内测试的需求日益减少然而，关于先天免疫反应，还有很多东西需要了解。 Core D 创建其他模型以供使用的能力。基础研究以及预防和治疗功效测试的发展受到了重视以下五种致死挑战模型：C57BL/6-sfaH 中的甲型流感病毒